Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials

24 studies are recruiting for pancreatic ductal adenocarcinoma (pdac) in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

   This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment or two prior lines of treatment if treated with KRAS inhibitor. The drug,…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic Arizona, Phoenix, Arizona

   Locations

   8 in total

   Run by

   BicycleTx Limited

   See if you can join NCT07450859 on ClinicalTrials.gov

2. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clearview Cancer Institute, Huntsville, Alabama

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

3. Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

   This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed pancreatic ductal adenocarcinoma. Following screening, using a standardized administration pr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Helios CR Inc./RadNet, Cerritos, California

   Locations

   16 in total

   Run by

   SOFIE

   See if you can join NCT07217717 on ClinicalTrials.gov

4. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

5. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic - Scottsdale, Phoenix, Arizona

   Locations

   49 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07491445 on ClinicalTrials.gov

6. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of Arizona Cancer Center-North Campus, Tucson, Arizona

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07621718 on ClinicalTrials.gov

7. SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

   This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors. SKL35502 is an imaging agent used with SPECT scans to identify tumors with neurotensin receptor 1 (NTSR1), a protein found on some cancer cells, and to …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   United Theranostics, Glen Burnie, Maryland

   Locations

   5 in total

   Run by

   SK Life Science, Inc.

   See if you can join NCT07812805 on ClinicalTrials.gov

8. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07805954 on ClinicalTrials.gov

9. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

   This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   START- Los Angeles, Los Angeles, California

   Locations

   29 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07644559 on ClinicalTrials.gov

10. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, San Diego, California

    Locations

    9 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07227168 on ClinicalTrials.gov

11. Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

    The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study ai…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    ARTIDIS AG

    See if you can join NCT07542041 on ClinicalTrials.gov

12. Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

    The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Excel Diagnostics & Nuclear Oncology Center, Houston, Texas

    Run by

    Radiomedix, Inc.

    See if you can join NCT07733674 on ClinicalTrials.gov

13. EUS-RFA PANCARDINAL-1 Trial

    The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Hermann Hospital, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT04990609 on ClinicalTrials.gov

14. A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

    Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensiv…

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope Nat Medical Ctr, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT07224750 on ClinicalTrials.gov

15. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

    Locations

    38 in total

    Run by

    Kura Oncology, Inc.

    See if you can join NCT06026410 on ClinicalTrials.gov

16. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Davis Comprehensive Cancer Center, Sacramento, California

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

17. A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

    The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Johns Hopkins Hospital, Baltimore, Maryland

    Locations

    8 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07223047 on ClinicalTrials.gov

18. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

19. Nutrition Intervention for Pancreatic Cancer

    Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of lif…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Locations

    2 in total

    Run by

    Children's Hospital of Philadelphia

    See if you can join NCT07554560 on ClinicalTrials.gov

20. Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

    This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non m…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Diego Moores Cancer Center, La Jolla, California

    Run by

    University of California, San Diego

    See if you can join NCT06639724 on ClinicalTrials.gov

21. Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

    This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including fluorouracil, leucovorin, oxaliplatin, and liposomal irinotecan) is sa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Cancer Center, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT07030283 on ClinicalTrials.gov

22. Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

    This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, no…

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT03977233 on ClinicalTrials.gov

23. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    6 in total

    Run by

    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov

24. ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

    This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama

    Run by

    ProDa BioTech, LLC

    See if you can join NCT06182072 on ClinicalTrials.gov